Research reveals that mesenchymal stem cell therapies improve pregnancy outcomes in women with recurrent spontaneous abortion, suggesting new treatment possibilities.
Young women’s physical and mental health is seriously impacted by recurrent spontaneous abortion (RSA), a prevalent obstetric complication that is becoming more commonplace worldwide. Therefore, a thorough investigation into the pathophysiology of RSA and the development of novel therapeutic strategies are imperative. Recent developments suggest that mesenchymal stem cell (MSC)-based therapies may be viable for addressing RSA. Through a variety of mechanisms, the immunological circumstances at the maternal-fetal contact can be altered, including regulating immune cell homeostasis, enhancing immune tolerance, alleviating inflammatory responses, promoting angiogenic processes, and promoting tissue regeneration. MSCs exhibit a remarkable capacity for multi-differentiation that could enhance pregnancy outcomes. This article provides compelling studies supporting the efficacy of MSC-based therapies in improving pregnancy outcomes in women with RSA.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: